https://mindmedicinelaw.com/briefing/party-drug-shows-promise-for-resistant-depression-treatment-20260628-17317The Psychedelic Journalen2026-06-28T15:04:24.344468+00:00Party Drug Shows Promise for Resistant Depression Treatmentresistant depression, recreational drug, mental health treatment, psychedelic research, clinical trials, neurotransmitter systems, regulatory challenges, treatment options, suicidal thoughts, drug efficacyhttps://mindmedicinelaw.com/briefing/psilocybin-nears-fda-approval-impact-on-therapy-and-market-20260628-17316The Psychedelic Journalen2026-06-28T15:04:08.088647+00:00Psilocybin Nears FDA Approval: Impact on Therapy and Marketpsilocybin, FDA approval, psychedelic therapy, mental health treatment, clinical trials, market dynamics, regulatory frameworks, psychedelic research, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/vortioxetine-s-potential-in-alzheimer-s-preclinical-insights-20260626-17252The Psychedelic Journalen2026-06-28T15:04:33.936470+00:00Vortioxetine's Potential in Alzheimer's: Preclinical Insightsvortioxetine, Alzheimer's disease, cognitive function, rat model, clinical trials, neuroprotection, Amyloid-β1–42, neuroscience, preclinical study, neurodegenerationhttps://mindmedicinelaw.com/briefing/psychosocial-protocols-in-psychedelic-therapy-a-scoping-review-20260626-17205The Psychedelic Journalen2026-06-28T15:04:16.104466+00:00Psychosocial Protocols in Psychedelic Therapy: A Scoping Reviewpsychedelic therapy, psychosocial protocols, standardization, mental health, research transparency, cultural responsiveness, clinical trials, psychedelic substances, therapy evaluation, interdisciplinary researchhttps://mindmedicinelaw.com/briefing/psilocybin-for-suds-rct-review-highlights-efficacy-and-challenges-20260626-16933The Psychedelic Journalen2026-06-27T15:04:27.822422+00:00Psilocybin for SUDs: RCT Review Highlights Efficacy and Challengespsilocybin-assisted therapy, substance use disorders, randomized controlled trials, functional unblinding, psychedelic research, safety and efficacyhttps://mindmedicinelaw.com/briefing/louisiana-s-psychedelic-therapy-pilot-a-new-model-for-state-healthcare-20260626-16852The Psychedelic Journalen2026-06-26T22:03:31.854875+00:00Louisiana's Psychedelic Therapy Pilot: A New Model for State HealthcareLouisiana psychedelic therapy, opioid settlement funding, state healthcare innovation, psilocybin therapy, MDMA treatment, mental health reform, psychedelic pilot program, substance abuse treatment, healthcare policy, psychedelic researchhttps://mindmedicinelaw.com/briefing/chris-letheby-s-philosophy-of-psychedelics-an-ethical-framework-20260625-16936The Psychedelic Journalen2026-06-27T15:04:58.979960+00:00Chris Letheby's Philosophy of Psychedelics: An Ethical Frameworkphilosophy of psychedelics, Chris Letheby, ethical framework, psychedelic research, therapeutic psychedelics, psychedelic policy, consciousness studies, psychedelic ethics, Oxford University Press, psychedelic communityhttps://mindmedicinelaw.com/briefing/dopamine-signaling-in-mdd-ventral-striatum-perfusion-insights-20260625-16944The Psychedelic Journalen2026-06-27T15:04:49.009005+00:00Dopamine Signaling in MDD: Ventral Striatum Perfusion Insightsdopamine signaling, major depressive disorder, ventral striatum, cerebral blood flow, anhedonia, amisulpride, dopaminergic mechanisms, reward processing, clinical trials, neurosciencehttps://mindmedicinelaw.com/briefing/pharmacogenomics-in-anaesthesia-evidence-and-future-directions-20260625-16943The Psychedelic Journalen2026-06-27T15:04:39.236174+00:00Pharmacogenomics in Anaesthesia: Evidence and Future Directionspharmacogenomics, anaesthesia, analgesia, personalized medicine, genetic polymorphisms, clinical trials, drug metabolism, perioperative carehttps://mindmedicinelaw.com/briefing/psychedelics-for-resistant-depression-efficacy-and-safety-20260625-16670The Psychedelic Journalen2026-06-26T22:03:52.607513+00:00Psychedelics for Resistant Depression: Efficacy and Safetypsychedelics, resistant depression, clinical trials, neuroplasticity, mental health policy, adverse effects, evidence-based practices, psychiatry, therapeutic protocols, regulatory changeshttps://mindmedicinelaw.com/briefing/exploring-very-low-dose-methylphenidate-in-behavioral-studies-20260624-16671The Psychedelic Journalen2026-06-26T22:04:02.145330+00:00Exploring Very-Low-Dose Methylphenidate in Behavioral Studiesvery-low-dose methylphenidate, functional activation, behavioral change, controlled testing, stimulant risks, cognitive enhancement, dose precision, pharmacological probe, ethical considerations, habit formationhttps://mindmedicinelaw.com/briefing/ketamine-assisted-psychotherapy-for-methamphetamine-insights-20260624-16634The Psychedelic Journalen2026-06-26T15:06:48.862373+00:00Ketamine-Assisted Psychotherapy for Methamphetamine: Insightsketamine-assisted psychotherapy, methamphetamine use disorder, qualitative study, psychological space, behavioral change, substance use treatmenthttps://mindmedicinelaw.com/briefing/4-br-dmt-synthesis-evaluation-and-future-implications-20260623-16697The Psychedelic Journalen2026-06-26T22:03:42.351427+00:004-Br-DMT: Synthesis, Evaluation, and Future Implications4-Br-DMT, serotonergic activity, psychedelic research, tryptamine analogs, drug development, safety profile, structure–activity relationshipshttps://mindmedicinelaw.com/briefing/lc-ne-system-s-role-in-early-alzheimer-s-symptoms-20260622-16195The Psychedelic Journalen2026-06-26T22:04:21.600099+00:00LC-NE System's Role in Early Alzheimer's Symptomslocus coeruleus-norepinephrine system, early Alzheimer's symptoms, neuropsychiatric symptoms, biomarker-driven interventions, neuroimaging advances, clinical trials, public health, disease progression, therapeutic targets, neuromodulatory interventionshttps://mindmedicinelaw.com/briefing/hypnosis-and-meditation-in-mental-health-a-new-frontier-20260622-16169The Psychedelic Journalen2026-06-26T22:04:13.169261+00:00Hypnosis and Meditation in Mental Health: A New Frontier?hypnosis, meditation, mental disorders, non-pharmacological adjuncts, randomized controlled trials, cognitive behavioral therapy, neuroimaging, psychological resilience, standardized guidelines, integrative treatmenthttps://mindmedicinelaw.com/briefing/synuclein-s-impact-on-pfc-in-parkinson-s-and-dementia-20260620-16137The Psychedelic Journalen2026-06-27T15:05:21.041770+00:00α-Synuclein's Impact on PFC in Parkinson's and Dementiaα-Synuclein, prefrontal cortex, Parkinson's Disease, Dementia with Lewy bodies, synaptic modulation, neuroprotective strategies, cognitive deficits, synaptic failure, glutamatergic synapses, GABAergic synapseshttps://mindmedicinelaw.com/briefing/neurodevelopmental-integrity-rethinking-substance-risk-20260620-16641The Psychedelic Journalen2026-06-27T15:05:11.663589+00:00Neurodevelopmental Integrity: Rethinking Substance Riskneurodevelopmental integrity, substance risk, developmental stages, public health, harm reduction, substance education, vulnerability, adolescents, young adults, policy implicationshttps://mindmedicinelaw.com/briefing/propofol-ketamine-neuroprotective-effects-in-oxidative-stress-20260618-16257The Psychedelic Journalen2026-06-27T22:04:08.668942+00:00Propofol & Ketamine: Neuroprotective Effects in Oxidative Stresspropofol, ketamine, oxidative stress, neuroprotection, A549 cells, clinical research, neurodegenerative diseases, antioxidant defense, psychedelic research, therapeutic strategieshttps://mindmedicinelaw.com/briefing/music-s-role-in-psychedelic-therapy-trials-a-review-20260615-15139The Psychedelic Journalen2026-06-27T22:04:31.532394+00:00Music's Role in Psychedelic Therapy Trials: A Reviewpsychedelic therapy, clinical trials, music playlists, psychotherapy, treatment efficacy, standardized guidelines, patient experience, therapeutic outcomes, neuroscience, policy implicationshttps://mindmedicinelaw.com/briefing/ketamine-s-role-as-an-antidepressant-clinical-insights-20260615-15470The Psychedelic Journalen2026-06-27T22:04:20.704975+00:00Ketamine's Role as an Antidepressant: Clinical Insightsketamine, antidepressant, clinical trials, mental health, NMDA receptors, treatment-resistant depression, psychiatry, neuroscience, FDA approval, mental health policyhttps://mindmedicinelaw.com/briefing/berberine-s-potential-in-multiple-sclerosis-therapy-20260614-15092The Psychedelic Journalen2026-06-27T22:04:51.558597+00:00Berberine's Potential in Multiple Sclerosis Therapyberberine, multiple sclerosis, clinical trials, immunomodulatory, neuroprotective, bioavailability, nanoformulations, JAK/STAT pathway, SPHK1/S1P pathwayhttps://mindmedicinelaw.com/briefing/designer-drugs-nps-chemistry-and-forensic-challenges-20260614-14590The Psychedelic Journalen2026-06-27T22:04:41.572239+00:00Designer Drugs & NPS: Chemistry and Forensic Challengesdesigner drugs, novel psychoactive substances, forensic challenges, public health, regulatory changes, analytical techniques, AI-assisted forensic, drug abuse trends, toxicological effects, global patternshttps://mindmedicinelaw.com/briefing/patient-driven-care-in-psychedelic-therapy-implications-and-challenges-20260613-15138The Psychedelic Journalen2026-06-27T22:05:03.156838+00:00Patient-Driven Care in Psychedelic Therapy: Implications and Challengespatient-driven care, psychedelic therapy, patient autonomy, personalized treatment, therapeutic outcomes, clinical trials, public health, ethics in therapy, standardized protocols, policy implications